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ERK1/2Human Apolipoprotein D (apoD) is upregulated under several stress conditions and pathological situations such
as neurodegenerative diseases and cancers. We previously showed that apoD mRNA expression is induced in
growth-arrested cells and demonstrated the speciﬁc binding of nuclear proteins to the region−514 to−475 of
the promoter. Such region contains a pair of Serum Responsive Elements (SRE), an Ets-Binding Site (EBS) and a
Glucocorticoid Responsive Element (GRE). In this study, we show that Parp-1, HnRNP-U, CBF-A, BUB-3, Kif4,
APEX-1 and Iﬁ204 bind these regulatory elements of the apoD promoter. Speciﬁc binding ofHnRNP-U and Parp-1
was conﬁrmed by Electrophoretic Mobility Shift Assay (EMSA). In a biotin pull-down assay, Kif4 and BUB-3 bind
preferentially the SRE1 and the EBS-GRE sites, respectively, while APEX-1 seems recruited indirectly to these
elements.We found that themRNAexpression of someof these binding factors is upregulated ingrowth-arrested
cells and that these proteins also transactivate the apoD promoter. In agreement with these results, mutants of
APEX-1 and of Parp-1 defective for their DNA-binding and catalytic activities could not transactivate the
promoter. The knockdownof Parp-1 andHnRNP-Uand theuse of speciﬁc inhibitors ofMEK1/2 and of Parp-1 also
inhibited the induction of apoD gene expression. Moreover, ERK1/2 was found activated in a biphasic manner
post serum-starvation and the inhibition of Parp-1 causes a sustained activation of ERK2 but not ERK1 for up
to 2 h. Altogether, these ﬁndings demonstrate the importance of Parp-1, APEX-1 and ERK1/2 catalytic activities
in the growth arrest-induced apoD gene expression.responsive element; EBS, Ets-
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Human apolipoprotein D (apoD) is a 29-kDa secreted glycoprotein
and a member of the lipocalin superfamily [1,2]. Since its discovery,
which dates for more than 35 years ago [3] and despite the
identiﬁcation of a variety of candidate ligands such as arachidonic
acid [4], progesterone and pregnenolone [5,6], bilirubin [7], E-3-
methyl-2-hexenoic acid [8] and cholesterol [9], the physiological
function of apoD remains unknown. Therefore, apoD is considered as a
protein with pleiotropic functions depending on its ligands and its
tissues or organs of expression [10].
In human, the apoD gene is expressed at high levels in the adrenal
glands, spleen, testes, lungs, pancreas, kidneys and the nervous system[10]. ApoD expression is also found increased in several neurological
disorders such as Alzheimer's disease, meningoencephalitis, dementia,
motor neuron disease [11], Parkinson's disease [12], schizophrenia
[13,14], multiple sclerosis [15] and several animal models of neurode-
generative injuries [10]. Besides neuropathological situations, apoD
expression is elevated in several cancers. This overexpression of apoD
gene is observed particularly in differentiated tumours with low prolif-
eration rate and several studies suggested the importance of cellular
growth arrest as a triggering factor of apoD expression [16–18].
Effectively, in cultured cells, apoD expression is associated with cellular
growth arrest, senescence and inﬂammation. In agreement with these
facts, apoD is also upregulated in aging rats [19] and humans [20,21]
and this senescence characteristic, which is an irreversible growth-
arrested state in contrary to quiescence, is also considered as a physiolo-
gical mechanism capable of counteracting tumour proliferation [22–26].
Furthermore, apoD expression and proliferation are also inversely
correlated in response to cellular stress. Indeed, cellular stressesprovoking
an extended growth arrest such as high doses of UV light and H2O2
increased apoD expression [27].
We have already identiﬁed the promoter region comprised between
−558 and −179 to be responsible for the induction of apoD following
growth arrest [28]. More precisely, we found that the Alternating Purine-
Pyrimidine stretch (APP) and two Serum Responsive Elements (SRE-1
and -2) were the major determinants of growth arrest-induced apoD
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of dyad symmetry [29]. Only the SRE1 of the apoD promoter contains
a CArG-box core described as a 10-bp element with the consensus
sequence CC(A/T)6GG. In many growth-related or immediate early
genes, the CArG-box element is often in the vicinity of an Ets-Binding-
Site (EBS) [29–33]. Detailed analysis of the apoD promoter also revealed
the presence of an EBS and a Glucocorticoid Responsive Element
(GRE) between the two SREs in the region−514 to−475 [28]. The EBS,
with its central core sequence 5'-GGA(A/T)-3', is known to cooperate
tightly with the SRE through the binding of several nuclear proteins,
particularly the Serum Response Factor (SRF) and members of the
E26 transforming speciﬁc (ETS) family which regulate several genes
implicated in cell proliferation and differentiation [33,34]. Also, the
GRE is known to interact with the Glucocorticoid Receptor (GR), a
nuclear receptor ligand-dependant transcription factor which recog-
nizes the consensus sequence 5'-GGTACAnnnTGTTCT-3' [35].
Thus, it appeared important to further study the regulation of the
apoD gene, especially in relation with cellular proliferation. As the SREs
in the region −558 to −179 were identiﬁed as major determinants
of growth arrest-induced gene expression, we focused our study on
this region of the promoter that contains the SRE1, EBS and GRE sites
(Table 1). Here, we present the identiﬁcation and the characteriza-
tion of several nuclear proteins that bind the apoD promoter under
normal and growth arrest conditions in NIH/3T3 ﬁbroblast cells. Our
results show that Parp-1, HnRNP-U, CBF-A, BUB-3, Kif4, APEX-1 and
Iﬁ204 bind elements of the promoter. We also investigated the
implication of MEK/ERK pathway in the regulation of the apoD gene
expression. We demonstrate the implication of these nuclear factors
in the modulation of the apoD promoter and that Parp-1, APEX-1 and
ERK1/2 catalytic activities regulate positively the apoD gene expres-
sion in growth arrested-cells.2. Materials and methods
2.1. Cell culture and reagents
Mouse ﬁbroblasts (NIH/3T3) were obtained from American Type
Culture Collection (ATCC, Rockville, MD) and maintained in Dulbec-
co's modiﬁed Eagle medium (DMEM; Invitrogen, Carlslab, CA)
supplemented with 10% calf serum, penicillin G (100 units/ml) and
streptomycin (100 μg/ml). NIH/3T3 cells were maintained at 37 °C in
a 5% CO2 humidiﬁed atmosphere and were fed every 2 days with
freshmedium. For the analysis of gene expression in sparsely growing
cultures (normal conditions), cells were maintained in medium sup-
plemented with 10% calf serum and harvested at 50% of conﬂuence. For
the analysis in growth arrest conditions, cells were maintained in 0.5%
serum when they reached 80% of conﬂuence. Cells were kept in this
medium and harvested at different days post serum starvation. When
speciﬁc inhibitors of Parp-1 or MEK1/2 were used, the medium was
replaced by medium containing 10 mM 3-ABA (Sigma, St. Louis, MO) or
10 μMU0126 (CalbiochemEMDBiosciences, SanDiego, CA), respectively.Table 1
Oligonucleotides used for the binding assay in EMSA and the streptavidin-biotin Technique
*Lower case letters, mutated nucleotides.2.2. Whole cell and nuclear extracts
For total extracts, 3×106 cells were lysed in 100 μl lysis buffer (10 mM
HEPES, pH 7.9, 140 mM NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40, 1 mM
PMSF, 1 mMdithiothreitol (DTT), 100 U/μl aprotinin and 200 μMSodium
orthovanadate (Na3VO4)). After 5 min of incubation at 4 °C, lysates were
cleared by 10 min of centrifugation at 13,000g at 4 °C. Nuclear extracts
(NE) from growing or from 5-day serum starved NIH/3T3 ﬁbroblasts
were prepared as described previously [36]. The protein concentration
was determined at 595 nm using the Bio-Rad protein assay reagent (Bio-
Rad Laboratories, Hercules, CA).
2.3. Electrophoretic mobility shift assays (EMSA)
Sense oligonucleotides (50 ng) were 5'-end-labeled with T4
polynucleotide kinase and (γ-32P) ATP and annealed with 200 ng of
the complementary oligonucleotide resulting in a double-stranded
sequence with SRE1-EBS-GRE elements found in the apoD promoter
and shown in Table 1. Nuclear extracts were added to 0.8 ng of the
labeled double-stranded oligonucleotide and after 20 min incubation
at room temperature, the mixture was run on a 6% acrylaminde, non-
denaturating gel in 0.5× TBE. The dried gels were autoradiographed
on Kodak X-Omat ﬁlms (Perkin Elmer, Rochester, NY). For competi-
tion assays, a 25- and 50-fold excess of cold double-stranded speciﬁc
and unrelated (UNR) oligonucleotide, shown in Table 1, was incu-
bated with the nuclear extracts before addition of labeled oligonu-
cleotide. For supershift assays, 20 and 50 μg of nuclear extracts were
incubated with speciﬁc antibodies against HnRNP-U (Santa Cruz
Biotechnology, Santa Cruz, CA) and Parp-1 (Chemicon, Temecula, CA).
2.4. Afﬁnity puriﬁcation of nuclear factors
The biotinylated oligonucleotides corresponded to the region –514
to –475 of the apoD promoter (SRE1-EBS-GRE) or carried mutations
on the cis elements; SRE1 and EBS-GRE. As negative control, the
IRU5Cas sequence from the Cas-Br-E retrovirus was used (Table 1).
Streptavidin beads (500 μg; Dynabeads M-280 Strepavidin, Dynal
Biotech, Oslo, Norway) were resuspended and incubated with 1500
pmoles of biotinylated oligonucleotides for 15 min in the buffer W&B
(1×) (10 mM of Tris–HCl, pH 7.5, 1 M of NaCl and 1 mM of EDTA) as
recommended by the manufacturer. The washing steps were done
in the same buffer and the beads linked with the biotinylated
oligonucleotideswere incubated for 15 min at room temperature with
500 µg of nuclear extracts containing 20 µl of annealing buffer 10×
(50 mM of Tris-HCl, pH 7.5, 1 M of NaCl, 100 mM of MgCl2, 0.2 mM
of EDTA and 1 mM of DTT), 1 mg of BSA and 20 μg of PolydI:dC in a
ﬁnal volume of 200 μl. The beads were washed with a low salt
washing buffer (20 mM Tris–HCl, pH 8.0, 0.05% NP-40, 1 mM EDTA
and 75 mM KCl) and eluted with 30 μl of SDS 0.1%. The proteins were
loaded on a SDS-PAGE (12%) and migrated at 100 V for 1 h followed
by silver nitrate staining or western blot analysis. For the silver nitrate.
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etry (LC-MS/MS) at the Genome Québec Innovation Centre Proteo-
mics Platform (Montreal, Qc, Canada) for protein identiﬁcation.2.5. Western blot
Protein extracts were eluted from the streptavidin–oligo complex,
heated for 10 min at 70 °C and loaded onto a 12% SDS-polyacrylamide
gel. The gel was subjected to electrophoresis for 1 h at 100 V and then
transferred by electroblotting to a polyvinylidene diﬂuoride (PVDF,
Millipore, Bedford, MA) membrane for 45 min at 300 mA. Membranes
were blocked for 1 h at room temperature with blocking buffer (PBS
containing 0.2% Tween 20 and 5% skim milk powder) and incubated
overnight at 4 °C with anti-mouse Parp-1 (1:1000), anti-mouse BUB-3
(1:1000; BD Transduction Laboratories, Mississauga, Ontario), anti-
mouse APEX-1 (1:1000; Santa Cruz Biotechnology), anti-rabbit Kif4
(1:500; Imegenex CEDERLANE Laboratories, Hornby, Ontario), anti-
rabbit ERK1/2 (1:1000; Cell Signaling Technology, Danver, MA) or
anti-rabbit phospho-ERK1/2 (1:1000; Cell Signaling Technology)
polyclonal antibodies in the blocking buffer. Subsequently, the blots
were incubated at room temperature with a secondary horseradish
peroxidase conjugated anti-mouse or anti-rabbit antibody (1:5000; GE
Healthcare Bio-Sciences, Little Chalfont, UK) in the blocking buffer.
The blots were developed using the enhanced chemiluminescence
method with Kodak X-Omat ﬁlms (Perkin Elmer) with X-ray ﬁlm.2.6. Semi-quantitative RT-PCR and siRNA transfections
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen,
Mississauga, Ontario). RNA was reverse-transcribed using Omniscript
Reverse Transcription Kit (Qiagen) according to the manufacturer's
instructions. The reverse transcriptase products (20 ng) were used
for ampliﬁcation of apoD, HnRNP-U, Parp-1, BUB-3, Kif4, Iﬁ204, APEX-1
or GAPDH genes using speciﬁc primers shown in Table 2. The ratio
obtained from sparse cultures at day 0 (D0) was given an arbitrary value
of one. All reactions were done in triplicate. For the siRNA experiments,
only 5 ng of the reverse transcriptase products were used. Two pre-
designed siRNA were used per gene: (HRNPU: Mm_Hnrpu_1 HP siRNA
or Mm_Hnrpu_5 HP siRNA; Parp-1: Mm_Parp1_3 HP siRNA or Mm_
Parp1_4 HP siRNA; Qiagen) and negative controls siRNAs (Allstar
negative control, Qiagen) were included in each experiment. All trans-
fections were done twice in triplicate.Table 2
Primers used for gene expression analysis by RT-PCR and mutagenesis.
Gene Primers sequence forward
Primers for RT-PCR
ApoD 5'-CCACCGGCACCCTACTGGATC-3'
HnRNP-U 5'-GAAGAAGAAGACGAACACTTCGA-3'
Parp-1 5'-ATGGCGGAGGCCTCGGAGAG-3'
BUB-3 5'-ATGACCGGTTCGAACGAATTCAA-3'
Kif-4 5'-ATGAAAGAAGAGGTGAAGGGGA-3'
Iﬁ204 5'-ATGGTGAATGAATACAAGAGAATTG-3'
APEX-1 5'-ATGCCAAAGCGGGGAAAGAAAG-3'
GAPDH 5'-GGTGAAGGTCGGTGTGAACGG-3'
Primers for mutagenesis
Del-Parp-1 5'-GTTAAGCTTGCAGCACGAGAAGGAGGATGGC-3' (fo
Del-Parp-1 5'-CAGCAGCCTCCGGTCTAGAAAGCTGCA-3' (reverse)
APEX-1 5'-GTTAAGCTTGGGCTTTCGTCACAGCGATGCC-3'(forw
APEX-1 5'-GCTTTCTAGACAGTGCTAGGTAAAGGGTGATG-3' (r
*C64A 5'-CCACACTCAAGATAgcCTCCTGGAATGTGG-3'
*C92A 5'-ACCAGATATCTTGgcCCTCCAACACACCAA-3'
*K6R/K7R 5'-GTTAAGCTTGGGCTTTCGTCACAGCGATGCCAAAGC
*D218A 5'-ATGAAGAAATTGcCCTCCGTAACCCCAAAG-3'
*, amino acid mutated in APEX-1 gene; lower case letters bold, mutated nucleotide; upper2.7. Luciferase assays
The cDNA of Parp-1, HnRNP-U, Iﬁ204, BUB-3 and APEX-1 were
cloned in pcDNA3.1A expression vector (Invitrogen, Burlington,
Ontario). Mutants of APEX-1 and Parp-1 were created by PCR directed
mutagenesis using speciﬁc primers listed in Table 2. The mutants of
APEX-1 were named C64A/C92A, K5R/K7R, D218A and Parp-1 lacking
its catalytic domain: del-Parp-1. The mutated cDNA were cloned in
pcDNA 3.1A in fusion with myc tag. Each plasmid was transiently co-
transfected in NIH/3T3 cells in the presence of Polyfect (Qiagen) as
recommended by the manufacturer, with a vector containing the
apoD promoter upstream of the luciferase reporter gene (−558/−4-
apoD-Luc). Twenty-four hours later, cells were rinsed twice with
phosphate-buffered saline and maintained in a medium supplemen-
ted with 10 or 0.5% serum. Transfected cells were lysed 48 h later and
luciferase activity was measured with the Dynex MLX microplate
luminometer (MLX Dynex Technologies, Chantilly, VA) as already
described [28]. Each sample was co-transfected with the β-gal-
expressing vector for normalization (pRSVβ-GAL). The β-galactosidase
activity was measured using the Galacto-Light™ kit (Applied Biosys-
tems, Bedford, MS) according to manufacturer's suggestions. Luciferase
activity is presented in Relative Light Units (RLU) and represents the
calculated mean±SD of nine transfected samples normalized by the
measured β-galactosidase activity.
2.8. Statistical analysis
Statistical signiﬁcance of the experiments was evaluated using
an unpaired Student's t-test. Results were considered statistically
signiﬁcant at Pb0.05.
3. Results
3.1. Puriﬁcation and identiﬁcation of nuclear factors binding the apoD
promoter
To isolate the nuclear factors that bind to the apoD promoter,
nuclear extracts from NIH/3T3 cells cultured under normal (10%
serum; NE+) and serum-starved (0.5% serum; NE−) conditions were
incubated with a biotinylated oligonucleotide linked to streptavidin
beads. This oligonucleotide contained the SRE1 with a CArG-Box core,
as well as the EBS and the GRE sites of the apoD promoter, shown in
Table 1 and named SRE1-EBS-GRE herein. The proteins were eluted
from the stretpavidin–oligo complex and visualized by SDS-PAGE andPrimers sequence reverse
5'-CGGGCAGTTCGCTTGTTGATCTGT-3'
5'-AAAATTTCGCTTCTTACGGGCAG-3'
5'-TCTGGATCCACCATCTTCTTGGACAG-3'
5'-TTACGTGGACTTGGGCTTTGTTT-3'
5'-GTAGCTTTCTCACGAGATGAAC-3'
5'-TCCAGTGATGTTTCTCCTCTTA-3'
5'-CAACGCTGTCGGTATTCCAG-3'
5'-ATGGGGGCATCGGCAGAAGG-3'
rward)
ard)
everse)
GGGGAAgGAgA-3'
case bold, restriction endonuclease site (forward, HindIII; reverse, XbaI).
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analysis based on their stronger intensity in NE (NE+, NE−)
compared to those obtained from streptavidin beads without bio-
tinylated oligonucleotide used as negative controls (CTRL+, CTRL−).
The corresponding bands in the negative controls were also analyzed
in order to eliminate false-negatives. Several nuclear proteins were
identiﬁed by correlating the mass of their tryptic peptides with the
theoric values found in NCBInr database through the Mascot server
(www.matrixscience.com) and listed in Fig. 1B.
Five of these proteins were known to interact directly or indirectly
with regulatory elements in the promoter of several genes and to
modulate their expression, notably, Heterogeneous nuclear ribonu-
cleoproteins (HnRNP)-U [37] and HnRNP-A/B also known as CArG-box
Binding Factor A (CBF-A) [38,39], Poly(ADP-ribose) polymerase-1
(Parp-1) [40], Interferon-inducible protein 204 (Iﬁ204) [41] and
Apurinic/Apyrimidinic Endonuclease-1 (APEX-1) [42,43]. Kinesin familyFig. 1. Puriﬁcation of nuclear proteins binding to the SRE1-EBS-GRE elements of the
human apoD promoter. (A) Nuclear extracts from normal growth (10% serum: +) or
growth arrest (0.5% serum:−) conditions were incubated with either the biotinylated
oligonucleotide bound to streptavidin beads (NE) or streptavidin beads alone (CTRL).
The bound proteins were eluted and analyzed by SDS-PAGE and silver staining. The
numbers and arrows on the gel indicate the excised bands. (B) Mass-spectrometry
analysis of the eluted bands. Nuclear factors were identiﬁed by mass spectrometry
(LC-MSMS) after tryptic digestion. STD: Standard molecular weight in kDa; this
experiment was done in duplicate.member 4 (Kif4) and Budding Uninhibited by Benzimidazole (BUB)-3
were also considered because of their role in cellular proliferation and
their interaction with Parp-1 [44,45]. As shown in Fig. 1A, CBF-A, BUB-
3 and APEX-1 were puriﬁed in both normal and growth arrest
conditions. In growth conditions, the two known isoforms of CBF-A
(p37 & p42) [46] were co-puriﬁed (lane 1; bands 5 and 7) in contrast
to growth arrest conditions where only the p42 isoform was puriﬁed
(lane 3; band 6). HnRNP-U, Parp-1 (band 2), Iﬁ204 (band 3), Septin 9
and Kinesin family member C1 (KifC1) (band 4) were exclusively
present in growth arrest conditions while Kif4 (band 1) only in normal
growth conditions. Several other band differences were observed but
the protein concentration was under the mass spectrometry limit of
detection.
3.2. PARP-1, HnRNP-U, Kif4, BUB-3 and APEX1 bind to the apoD promoter
in vitro
In order to conﬁrm the binding speciﬁcity of the selected proteins
on the apoD promoter, we performed an electrophoretic mobility
supershift assay (EMSA) using commercially available antibodies
against these proteins. The same oligonucleotide as that used above
for the biotin–streptavidin puriﬁcation (Table 1) was radiolabeled and
incubated with nuclear extracts from serum-starved NIH/3T3 cells.
As shown in Fig. 2A, we observed several protein-DNA complexes
(CTRL+) compared to the negative control (CTRL−). In the presence
of an antibody directed against HnRNP-U, the complex corresponding
to band II disappeared (indicated with an asterisk). Competition assay
using cold (SRE1-EBS-GRE) and unrelated (UNR) oligonucleotides in
25 and 50 molar excess demonstrated the speciﬁcity of formed
complexes. In contrast, for Parp-1, 50 μg of nuclear extract were
required in order to detect the supershift. Four bands could be
detected but the two major (bands II and III) disappeared in favor of a
supershifted band (Fig. 2A, arrow). Although, the binding speciﬁcity of
these complexes was not veriﬁed in this experiment with cold
oligonucleotide excess, the intensity of band IV was increased in the
presence of 0.25 μg of Parp-1 speciﬁc antibodies and reduced
progressively with increasing amounts of antibodies (0.5 to 2 μg).
The antibodies directed against Kif4, BUB-3 and APEX-1 failed to
supershift the DNA-complexes observed (data not shown). However,
in a pull-down assay using biotinylated oligonucleotides containing
regulatory consensus sequences that were either intact or mutated
or deleted (Table 1), we observed by western blot that Kif4 was
preferentially bound to the SRE1 in growth conditions (Fig. 2B). In
growth arrest conditions, BUB-3 did not bind the SRE1-mEBS-mGRE
but was speciﬁcally bound to the mSRE1-EBS-GRE and the EBS-GRE
where the SRE1 had been mutated or deleted, respectively. APEX-1
could bind both the SRE1-mEBS-mGRE and the mSRE1-EBS-GRE but
not the EBS-GRE.
3.3. mRNA expression of nuclear factors in growth-arrested NIH/3T3 cells
We next analyzed the mRNA expression of these nuclear factors in
NIH/3T3 ﬁbroblasts to determine if they were also modulated by
growth arrest as the apoD gene. Cells were collected in growth
conditions and at different times after serum deprivation. Using
speciﬁc primers for the different genes (Table 2), their expression
level was analyzed by semi-quantitative RT-PCR and normalized to
that of GAPDH gene expression. As expected, apoD mRNA expression
was signiﬁcantly induced in serum starvation conditions (Fig. 3).
Expression levels of Parp-1 were also induced by 2.1-fold after 1 day
of serum starvation and reached a peak at day 2 with a 3-fold
induction to ﬁnally decrease until day 5. This induction was even
stronger by Northern analysis (up to 9 fold at day 2). Iﬁ204 and APEX-
1 were also induced after 2 days of serum starvation by respectively
2.8 and 1.8 fold. In contrast, Kif4 mRNA expression was down-
regulated after 2 days of serum starvationwhich is consistent with the
Fig. 2. Binding of HnRNP-U, PARP-1, Kif4, BUB-3 and APEX-1 to the apoD promoter. (A) Nuclear extracts from 5-day serum-starved NIH/3T3 mouse ﬁbroblasts were used in
electrophoretic mobility assay with double stranded oligonucleotides containing the SRE1-EBS-GRE of the apoD promoter. 20 µg (HnRNP-U) and 50 µg (Parp-1) of nuclear extracts
were incubated in the presence of 0.8 ng of radiolabeled probe and different amounts of speciﬁc antibodies. Unlabeled competitor nucleotides were added at 25- and 50-fold molar
excess. UNR: (unrelated) non-speciﬁc competitor; NE: nuclear extracts; (+): growth condition; (−): growth arrest condition; CTRL: negative control (probe only); Abs: speciﬁc
antibodies. The asterisks represent the disappearance of the DNA-complex and the arrow the supershifted DNA–protein complex. Representative of three similar experiments. (B)
Biotin pull-down assay using different probes in which sequence of speciﬁc regulatory element was mutated or deleted as indicated (Table 1). The eluted proteins were then
analyzed by western blot using speciﬁc antibodies against Kif4, BUB-3 and APEX-1. Sequence from the IRU5Cas LTR of Cas-Br-E retrovirus was used as negative control.
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conditions (Fig. 1A). In addition, HnRNP-U and BUB-3 were not
modulated under serum starvation and seem ubiquitous.
3.4. Transactivation of the apoD promoter
To determine if these nuclear proteins are directly involved in the
modulation of apoD gene expression, the corresponding cDNAs
cloned in expression vectors were transiently co-transfected in NIH/
3T3 cells with a construct containing the apoD promoter upstream
of the luciferase reporter gene (−558/−4-apoD-Luc) and with
pRSVβGAL vector. The luciferase activity was analyzed in normal
and serum-starved conditions. In growth conditions (10% serum;
Fig. 4A: white bars), none of the proteins tested had an effect on apoD
promoter activity compared to the control (empty vector). However,
after 2 days of serum starvation (0.5% serum; grey bars), Parp-1,
HnRNP-U, APEX-1 and Iﬁ204 signiﬁcantly activated the apoD
promoter. In contrast, BUB-3 did not transactivate the apoD promoter.
To conﬁrm these results, we created speciﬁc mutations on APEX-1
gene on cysteines 64 and 92 which were replaced by alanine (C64A/
C92A). These cysteines are known to be implicated in the redox
activity of APEX-1 which modiﬁes and modulates the activity ofseveral transcription factors [47]. Lysines 6 and 7, located in the
nuclear localization signal motif (NLS) and known to be acetylated by
p300 were replaced by arginine (K6R/K7R). This double mutation
abrogates the redox activity of APEX-1 without affecting its nuclear
localization [48]. Finally, aspartic acid 218 which is known to be
important for the endouclease and DNA-binding activities [49] was
replaced by alanine (D218A). As shown in Fig. 4A, all these mutants
were unable to transactivate the apoD promoter in growth arrest
conditions in contrast with the wild type APEX-1. Interestingly,
mutants C64A/C92A and K6R/K7R induced the proliferation of NIH/
3T3 cells cultured in condition of serum starvation compare to the
wild-type APEX-1 or the control (CTRL−; empty vector) where the
cells were maintained in a growth arrest state (Supplemental Fig.1).
In addition, the Parp-1 deletion mutant lacking its catalytic domain
(del-Parp-1) could no longer transactivate the apoD promoter
indicating the importance of the catalytic function in the apoD
promoter regulation. Furthermore, we tested the role of Parp-1 and
HnRNP-U on the apoD expression using a siRNA approach. The pre-
designed siRNAs used to block either HnRNP-U or Parp-1 inhibited
their target gene expression by more than 80% up to 4 days under
growth arrest (grey bars; Fig. 4B) and efﬁciently and speciﬁcally
blocked apoD expression (grey bars; Fig. 4C).
Fig. 3. Analysis of mRNA expression of nuclear factors in NIH/3T3 growth arrested cells.
Semi-quantitative RT-PCR using speciﬁc primers for the indicated genes (Table 2). The
expression of each gene tested was normalized by GAPDH expression. (N=3, *Pb0.05,
**Pb0.01, ***Pb0.001). An example of one Northern analysis is presented for Parp-1.
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To further investigate the role played by the catalytic activity of
Parp-1 in the regulation of the apoD promoter during growth arrest,
we used 3-Amino-Benzamide (3-ABA), a speciﬁc inhibitor of Parp-1.
This inhibitor blocks the binding of NAD+ to the catalytic domain of
Parp-1. This binding is crucial for the transfer of ADP-ribose unit on
nuclear proteins mediated by Parp-1 [50]. As expected, the inhibition
of Parp-1 catalytic activity with 3-ABA at 10 mM completely abolished
the stimulating effect of Parp-1 on the apoD gene expression in
growth-arrested cells (Fig. 5A). This result was consistent with those
obtained with the deletional mutant del-Parp-1 transfection exper-
iment and the siRNA assay (Fig. 4A and C).
Furthermore, considering the important role played by the MEK/
ERK pathway in cellular proliferation and differentiation as well as the
interplay between ERK and Parp-1, which modulates their respective
catalytic activity [51,52], we also analyzed the effect of a MEK1/2
inhibitor (U0126 at 10 μM) on the apoD gene regulation. Interestingly,
the inhibition of MEK1/2, which phosphorylate ERK1/2, signiﬁcantly
reduced the apoD gene expression under growth arrest conditions
(Fig. 5B). Complete inhibition of ERK1/2 phosphorylation in presence
of U0126 was veriﬁed by western blot analysis (results not shown).
Consistent with this result, upregulation of phosphorylated ERK1/2
was detected as early as 5 min after serum starvation without inhibitor,
reached a peak at 15 min and decreased after 30min (Fig. 5C). Sur-
prisingly, at 24 h post serum starvation, ERK1/2 were again phosphor-
ylated. Moreover, in the presence of Parp-1 inhibitor, activation of ERK2,
but not ERK1, is maintained after 15 min for up to 2 h (Fig. 5D).
Subsequently, ERK2 phosphorylation was completely inhibited after2 h in the presence of Parp-1 inhibitor which is consistent with the
apoD gene downregulation observed in Fig. 5A and B.
4. Discussion
The apoD promoter was previously characterized and its com-
plexity is reﬂected by the numerous cis elements located within its
promoter [28,53]. Using a biotinylated oligonucleotide containing the
SRE1, EBS and GRE elements of the apoD promoter, we were able to
purify and identify several nuclear proteins by mass spectrometry
analysis. Among these proteins, HnRNP-U and CBF-A (Fig.1A), which
belong to the Heterogeneous nuclear ribonucleo-protein family, are
also known to interact with elements in the promoter of several genes
and to regulate their expression. Indeed, HnRNP-U is known as a
transcriptional activator of Kruppel-like factor 2 gene [54] and of
Osteopontine gene expression, which is also modulated by CBF-A [37].
CBF-A is also involved in the regulation of the Ha-ras gene ex-
pression [39]. The mRNA binding ability of these two proteins led us
to speculate that they could be recruited at the promoter level and play
a role in both the apoD mRNA expression and processing, in this
context of growth arrest. All these different crucial roles of HnRNP-U
may explain its ubiquitous gene expression proﬁle in growth-arrested
NIH/3T3 cells (Fig. 3). Binding of HnRNP-U to the promoter was
further demonstrated by EMSA (Fig. 2A). The addition of HnRNP-U
antibodies speciﬁcally reduced the complex intensity. This interaction
with the SRE1-EBS-GRE, whether direct or indirect, is in agreement
with previous reports showing that HnRNP-U can play a role in gene
regulation via its interaction with the GRE site located in the promoter
of the tryptophan oxygenase gene [55] and therefore suggests that
HnRNP-U might interact with the apoD promoter through the GRE
binding site.
Parp-1 is an abundant nuclear protein with a poly(ADP-ribosyl)-
ation catalytic activity which uses NAD+ as substrate to modify
several nuclear proteins, such as transcription factors thus affecting
their functions [40,56]. Although, several studies have shown its
implications in DNA repair pathways, its DNA-binding and catalytic
activities are also implicated in transcription regulation [40,56].
Despite the fact that Parp-1 is reported as a ubiquitous protein, we
found that its gene expression is up-regulated in growth-arrested
NIH/3T3 cells and we clearly demonstrated its binding to the apoD
promoter, highlighting its importance in this stress condition. We
were able to obtain a supershift by EMSA upon addition of a speciﬁc
antibody coupled with the disappearance with the major bands II and
III. Bands I and IV were very faint and detectable only when 50 μg of
extracts were used. Both bands appeared more abundant in growth
arrest conditions and seem speciﬁc since they disappeared in the
presence of Parp-1 antibodies (Fig. 2A).
In agreement with our results, Parp-1 can be activated by its
binding to conformational or non-B DNA structures such as cruciforms
or hairpins [57,58]. More importantly, cruciforms can be formed
within a sequence that contains inverted repeats with the appearance
of duplex arms. The SRE was already reported to be able to form
cruciforms which resemble the Holliday junction [59]. Moreover,
several studies demonstrated the interaction of Parp-1 with DNA in a
sequence-speciﬁc manner. Tapia-Paez and collaborators [60] reported
the binding of Parp-1 to a SRE-CArG-like element. Parp-1 was also
shown to bind a recently named Parp-1-binding element (PBE) [61]
whose consensus sequence resembles that of the GRE.
We were not able to conﬁrm binding by EMSA for the other
selected proteins for which speciﬁc antibodies were commercially
available most likely because the recognized epitope is hidden in the
protein native form. However, using the biotin pull-down approach
followed by western blot analysis, we conﬁrmed that these proteins
effectively bind the region of the promoter containing the SRE1, EBS
and GRE sites (Fig. 2B). Obviously, BUB-3 does not recognize the SRE1
since the protein still binds an oligo lacking the SRE1 or an oligo in
Fig. 4. ApoD mRNA induction in growth-arrested cells and siRNA analysis. (A) NIH/3T3 cells were co-transfected with vectors containing a luciferase reporter construct under
the 5'-ﬂanking region (−558/−4) of the apoD promoter gene, the cDNAs corresponding to the identiﬁed proteins or APEX-1 cDNA carrying mutations (C64A/C92A, K5R/K7R
and D218A) and the plasmid pRSVβGAL. After transfection, cells were cultured in media with (10%; white bars) or without serum (0.5%; grey bars) for 2 days. The luciferase
activity was analyzed and normalized by the β-Galactosidase activity. The empty pcDNA 3.1 expression vector was used as control. The asterisks indicate statistically signiﬁcant
results (N=9, *Pb0.05, **Pb0.01, ***Pb0.001). Del-Parp-1 corresponds to the protein lacking its C-terminal end and its enzymatic activity. (B) NIH-3T3 cells were transiently
transfected with siRNA directed against HnRNP-U and Parp-1 and exposed to serum-starved conditions for 4 days. Total RNA was extracted and analyzed by RT-PCR using
speciﬁc primers for the HnRNP-U, Parp-1 gene and HPRT as control. (C) ApoD mRNA expression analyzed by RT-PCR in NIH-3T3 cells exposed to serum starved conditions for
4 days after siRNA suppression of HnRNP-U and Parp-1 genes. As negative controls, transfections with non-speciﬁc siRNA (siRNA NS) or without siRNA (−siRNA) were used.
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the EBS, we also mutated the GRE as well as the SRE1 because these
sites are superimposed (see Table 1). Moreover, BUB-3 did not
modulate the apoD promoter (Fig. 4A) and the gene was not activated
under growth arrest (Fig. 3).
Based on our results, Kif4 binds the SRE1most probably through its
CArG-box core since it only binds the intact SRE1 (Fig. 2B) and as
already mentioned above, most of the mutated EBS consensus
sequence is included within the inverted repeat of the SRE1. Kif4 is
a member of the kinesin superfamily of proteins known to transport
cargos of macromolecules along the microtubules of cells, such as
membrane organelles, protein complexes and mRNAs [44,62]. The
Kif4 nuclear localization was shown to be regulated by its interaction
with Parp-1 in juvenile neurons. In addition, Kif4 can repress Parp-1
enzymatic activity in the nucleus of NIH/3T3 cells in normal culture
conditions [44]. Thus, the apoD gene expression could be modulated
by the interaction of these two proteins. In our study, Parp-1 could not
be puriﬁed in normal growth conditions suggesting that the possible
interaction of Parp-1 and Kif4 in NIH/3T3 cells, reported by
Midorikawa and collaborators [44], may inhibit Parp-1 binding on
the apoD promoter. Therefore, the presence of Parp-1 on the apoD
promoter in growth arrest conditions may be favored by both
the down- and upregulation in gene expression of Kif4 and Parp-1,
respectively (Fig. 3).
In contrast, APEX-1 binds the promoter but binding persists des-
pite themutations of each consensus sequence (Fig. 2B). However, thedeletion of the SRE1 abolished the binding. This implies that APEX-1
probably binds the apoD promoter through a greater afﬁnity for the
mutated sequences or through the interaction with other proteins,
such as Parp-1, that bind either the SRE1 or the EBS-GRE sites. APEX-1
is a multifunctional protein implicated in DNA repair through the
base-excision repair (BER) pathway, where Parp-1 was also shown to
be involved but more importantly, APEX-1 is well known for its role in
transcription regulation through a redox activity. Indeed, the redox
activity of APE1 was shown to modify and activate several stress-
inducible transcription factors such as AP-1, NF-κB, p53, Egr-1, CREB,
ATF and HIF-1α [47,63]. The fact that APEX-1 gene expression was
found induced in growth arrest conditions may also indicate its
importance in such stress conditions (Fig. 1B). Also, APEX-1 was
shown to be induced in several stresses such as oxidative conditions,
cancers [47] and several neurodegenerative disorders [63]. It is
interesting to note that such stresses including H2O2 and UV induce
apoD gene expression as well as the catalytic activity of Parp-1
[27,64,65]. Therefore, it would be of interest to investigate if Parp-1
and APEX-1 also modulate the apoD gene expression under these
conditions and will deﬁnitely clarify the mechanism of regulation of
the gene. Indeed, apoD is considered as a stress protein, and we
demonstrated that it plays a protective effect for neurons of mice
treated with paraquat [65]. A similar protection against oxidative
stress was observed in Drosophila and plants [65,66]. Protection was
also observed in mice infected with OC43, a coronavirus that induces
brain inﬂammation and neurodegeneration [64].
Fig. 5. Analysis of apoD mRNA expression in presence of Parp-1 and MEK1/2 inhibitors. NIH-3T3 cells were cultured under normal (10% serum, +) and serum starvation
(0.5% serum, −) conditions for 48 h with or without Parp-1 speciﬁc inhibitor: 3-Amino-Benzamide (3-ABA, 10 mM) (A) or MEK inhibitor: U0126 (10 μM) (B). Total RNA was
extracted and the expression of apoD gene was analyzed by RT-PCR. The GAPDH gene was used as internal control. The asterisk indicates statistically signiﬁcant results (N=4,
***Pb0.001). Western blots of the phosphorylation levels of ERK1/2 in NIH/3T3 cells under serum starvation at different time points (C) and in the presence of Parp-1 inhibitor (D)
(representative of three similar experiments).
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inducible p200 (Iﬁ-200) family of proteins induced by interferons (IFNs)
[67]. Due to the lack of speciﬁc antibodies against Iﬁ204, it was not
possible to conﬁrm its binding to the apoD promoter by EMSA.
However, the protein was clearly identiﬁed with a high score in the
streptavidine beads technique in extracts from growth arrest conditions
(Fig. 1B). More importantly, Iﬁ204 expression was induced under serum
starvation (Fig. 3). These results are consistent with the known
interaction of Iﬁ204 and the Retinoblastoma protein (pRb) which both
inhibit proliferation. Also, mutations in Iﬁ204 confer malignant transfor-
mation properties in NIH/3T3 cells [67,68].
In the transactivation assay, we showed that Parp-1, HnRNP-U,
APEX-1 and Iﬁ204 had a positive effect on the apoD promoter in
growth arrest conditions only (Fig. 4A). The positive effect of Parp-1
and HnRNP-U was also conﬁrmed by the knock down of their
expression with speciﬁc siRNA. Their inhibition totally abolished the
apoD gene induction under serum starvation conditions (Fig. 4C).
Moreover, we further demonstrated the importance of Parp-1 and
APEX-1catalytic activities in the induction of apoD gene expression in
growth-arrested cells. These results were observed either by deleting
the C-terminal portion containing the catalytic domain of Parp-1
(Fig. 4A) or by inhibiting its catalytic activity with a speciﬁc inhibitor
3-ABA (Fig. 5A). For APEX-1, both its redox and DNA-binding activitieswere necessary to transactivate the apoD promoter and we demon-
strate a link between APEX-1 redox activity and the cell cycle
regulation since inhibition of APEX-1 activity promotes cell prolifer-
ation under serum starvation (Supplemental Fig. 1). This is consistent
with the strong relation between the redox cycle and cell cycle
regulation [69,70].
We also found that the inhibition of MEK1/2 blocks apoD gene
induction by growth-arrest after 2 days showing the importance of this
pathway in the regulation of apoD gene expression. This is surprising
since ERK1/2 activation is essential for cell cycle progression from G1-
to S-phase by downregulating several antiproliferative genes [71,72].
However, ERK1, but not ERK2, expression in ﬁbroblasts inhibits
oncogenic Ras-mediated proliferation, colony formation as well as
tumor production in nude mice [73]. More importantly, the B-Raf
isoforms can induce cell-cycle arrest in NIH/3T3 cells [74]. In this study,
we showed biphasic ERK1/2 activation in time in growth-arrested NIH/
3T3 cells, reaching apeak at 15 min, decreasing after 30 min and activated
again 24 h later (Fig 5C). In addition, ERK2 remains phosphorylated for up
to 2 h in the presence of Parp-1 inhibitor which blocks apoD expression
(Fig. 5D). This result implies that ERK1/2 activation is necessary for apoD
gene induction. This regulation of ERK1/2 phosphorylation in growth
arrest conditions could be mediated by Parp-1 activity. Further investiga-
tions are necessary to verify if ERK1/2 are effectively ADP-(ribosyl)ated in
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involved in the regulation of the nuclear factors identiﬁed herein.
In conclusion, we identiﬁed several proteins that bind the apoD
promoter through the SRE1, EBS and GRE elements and regulate its
gene expression in growth arrest conditions. Our results also highlight
the implication of the MEK/ERK pathway in the apoD regulation, itself
modulated by Parp-1 catalytic activity. They demonstrate a central
role played by Parp-1 and APEX-1, both through their binding to the
apoD promoter and their catalytic activity during this process.
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